Next Article in Journal
Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature
Previous Article in Journal
Differences in Anxiety Levels of Various Murine Models in Relation to the Gut Microbiota Composition
Open AccessReview

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

1
Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
2
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan
*
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(4), 114; https://doi.org/10.3390/biomedicines6040114
Received: 10 November 2018 / Revised: 29 November 2018 / Accepted: 4 December 2018 / Published: 7 December 2018
The programmed death-ligand 1(PD-L1)/PD-1 pathway is an immunological checkpoint in cancer cells. The binding of PD-L1 and PD-1 promotes T-cell tolerance and helps tumor cells escape from host immunity. Immunotherapy targeting the PD-L1/PD-1 axis has been developed as an anti-cancer therapy and used in treating advanced human non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Yes-associated protein (YAP) is a key mediator of the Hippo/YAP signaling pathway, and plays important roles in promoting cancer development, drug resistance and metastasis in human NSCLC and MPM. YAP has been suggested as a new therapeutic target in NSCLC and MPM. The role of YAP in regulating tumor immunity such as PD-L1 expression has just begun to be explored, and the correlation between YAP-induced tumorigenesis and host anti-tumor immune responses is not well known. Here, we review recent studies investigating the correlation between YAP and PD-L1 and demonstrating the mechanism by which YAP regulates PD-L1 expression in human NSCLC and MPM. Future work should focus on the interactions between Hippo/YAP signaling pathways and the immune checkpoint PD-L1/PD-1 pathway. The development of new synergistic drugs for immune checkpoint PD-L1/PD-1 blockade in NSCLC and MPM is warranted. View Full-Text
Keywords: yes-associated protein (YAP); programmed death-ligand 1 (PD-L1); non-small cell lung cancer (NSCLC); malignant pleural mesothelioma (MPM); immunotherapy yes-associated protein (YAP); programmed death-ligand 1 (PD-L1); non-small cell lung cancer (NSCLC); malignant pleural mesothelioma (MPM); immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Hsu, P.-C.; Yang, C.-T.; Jablons, D.M.; You, L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 2018, 6, 114.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop